Mark Stenhouse's most recent trade in Phathom Pharmaceuticals Inc was a trade of 24,122 Common Stock done . Disclosure was reported to the exchange on May 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 24,122 | 54,122 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 10,500 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,500 | 19,500 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 9,000 | 9,000 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Mark Stenhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) |